Northwest Biotherapeutics, Inc.
NWBO
$0.23
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -65.07% | 62.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -65.07% | 62.34% | |||
| Cost of Revenue | -11.03% | -20.64% | |||
| Gross Profit | 8.49% | 22.50% | |||
| SG&A Expenses | -19.87% | 13.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.70% | -5.57% | |||
| Operating Income | 14.63% | 6.42% | |||
| Income Before Tax | 20.50% | 31.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.50% | 31.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.50% | 31.46% | |||
| EBIT | 14.63% | 6.42% | |||
| EBITDA | 15.10% | 6.56% | |||
| EPS Basic | 22.92% | 33.94% | |||
| Normalized Basic EPS | 25.00% | 41.94% | |||
| EPS Diluted | 22.92% | 33.94% | |||
| Normalized Diluted EPS | 25.00% | 41.94% | |||
| Average Basic Shares Outstanding | 5.79% | 3.97% | |||
| Average Diluted Shares Outstanding | 5.79% | 3.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||